First Time Loading...

Santen Pharmaceutical Co Ltd
TSE:4536

Watchlist Manager
Santen Pharmaceutical Co Ltd Logo
Santen Pharmaceutical Co Ltd
TSE:4536
Watchlist
Price: 1 512.5 JPY 1.41% Market Closed
Updated: Apr 30, 2024
Section:
 

Relative Value

The Relative Value of one Santen Pharmaceutical Co Ltd stock under the Base Case scenario is 1 627.18 JPY. Compared to the current market price of 1 512.5 JPY, Santen Pharmaceutical Co Ltd is Undervalued by 7%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
1 627.18 JPY
Undervaluation 7%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.8
P/S
P/S
Price to Sales
1.8
vs History
60
vs Industry
57
Median 3Y
1.7
Median 5Y
2.3
Industry
2.4
Forward
1.8
More Details
19.8
P/E
P/E
Price to Earnings
19.8
vs History
57
vs Industry
26
Median 3Y
18.4
Median 5Y
22
Industry
22.9
Forward
16.5
More Details
8.1
P/OCF
P/OCF
Price to OCF
8.1
vs History
92
vs Industry
39
Median 3Y
11.2
Median 5Y
13.9
Industry
17.1
More Details
10.3
P/FCFE
P/FCFE
Price to FCFE
10.3
vs History
92
vs Industry
29
Median 3Y
23.3
Median 5Y
27.5
Industry
23.2
More Details
1.8
P/B
P/B
Price to Book Value
1.8
vs History
49
vs Industry
43
Median 3Y
1.6
Median 5Y
1.8
Industry
2.1
More Details
1.7
EV/S
EV/S
Enterprise Value to Sales
1.7
vs History
61
vs Industry
59
Median 3Y
1.6
Median 5Y
2.1
Industry
2.6
Forward
1.6
More Details
2.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.7
vs History
60
vs Industry
64
Median 3Y
2.7
Median 5Y
3.4
Industry
5.1
More Details
7.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7.5
vs History
84
vs Industry
41
Median 3Y
10.1
Median 5Y
11.9
Industry
13.6
Forward
7.7
More Details
10.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
10.2
vs History
77
vs Industry
38
Median 3Y
11.4
Median 5Y
15
Industry
17
Forward
10.6
More Details
7.3
EV/OCF
EV/OCF
Enterprise Value to OCF
7.3
vs History
92
vs Industry
42
Median 3Y
10.2
Median 5Y
12.8
Industry
15.8
More Details
8.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
8.7
vs History
92
vs Industry
31
Median 3Y
33.2
Median 5Y
27.2
Industry
17.6
More Details
1.7
EV/IC
EV/IC
Enterprise Value to IC
1.7
vs History
50
vs Industry
42
Median 3Y
1.5
Median 5Y
1.7
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Santen Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Santen Pharmaceutical Co Ltd
TSE:4536
549.3B JPY 1.8 19.8 7.5 10.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
694.9B USD 20.4 132.6 59.9 68.8
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK 17.1 47.4 34.7 37.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
82T JPY 255.8 9 733.7 1 771.8 4 320.3
US
Johnson & Johnson
NYSE:JNJ
352.4B USD 4.3 8.7 11.6 15.3
US
Merck & Co Inc
NYSE:MRK
331.8B USD 5.5 909 45.1 88.1
UK
AstraZeneca PLC
LSE:AZN
186.4B GBP 5.1 39.3 141.3 226.6
CH
Novartis AG
SIX:NOVN
181.8B CHF 4.3 13.4 9.8 16.3
CH
Roche Holding AG
SIX:ROG
176.8B CHF 3 15.4 8.8 10.4

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 132,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.